National Cancer Institute
U.S. National Institutes of Health | www.cancer.gov

NCI Home
Cancer Topics
Clinical Trials
Cancer Statistics
Research & Funding
News
About NCI
Study of Tamoxifen and Raloxifene (STAR) Trial
    Posted: 07/27/2000    Updated: 09/12/2007



Introduction






STAR Background






STAR-At-A Glance






STAR Enrollment Statistics






STAR Images






STAR Publications



Page Options
Print This Page
Print This Document
View Entire Document
E-Mail This Document
Quick Links
Director's Corner

Dictionary of Cancer Terms

NCI Drug Dictionary

Funding Opportunities

NCI Publications

Advisory Boards and Groups

Science Serving People

Español
NCI Highlights
High Dose Chemotherapy Prolongs Survival for Leukemia

Prostate Cancer Study Shows No Benefit for Selenium, Vitamin E

Past Highlights
Related Pages
Breast Cancer Home Page
NCI's gateway for information about breast cancer.

U.S. Task Force: Chemoprevention of Breast Cancer
The U.S. Preventive Services Task Force has issued two recommendations concerning the use of prescription medicines such as tamoxifen in the prevention of breast cancer.

Estrogen Receptors, Tamoxifen, and Raloxifene
Describes the hormone estrogen and its receptor. Explains the relationship of estrogen and its receptor to breast cancer and the risks and benefits of reducing cancer risk with drugs called antiestrogens and selective estrogen receptor molecules (SERMs).
STAR Publications

The following citations are of reports that have been published in the scientific literature concerning the Study of Tamoxifen and Raloxifene (STAR). The citations are listed in reverse chronological order.

2006 Publications

Patient-Reported Symptoms and Quality of Life During Treatment With Tamoxifen or Raloxifene for Breast Cancer Prevention: The NSABP Study of Tamoxifen and Raloxifene (STAR) P-2 Trial

  • Authors: Land SR, Wickerham DL, Costantino JP, Ritter MW, Vogel VG, Lee M, Pajon ER, Wade JL 3rd, Dakhil S, Lockhart JB Jr, Wolmark N, Ganz PA
  • Journal: Journal of the American Medical Association 2006 Jun 21;295(23):2742-51

Effects of Tamoxifen vs Raloxifene on the Risk of Developing Invasive Breast Cancer and Other Disease Outcomes: The NSABP Study of Tamoxifen and Raloxifene (STAR) P-2 Trial

  • Authors: Vogel VG, Costantino JP, Wickerham DL, Cronin WM, Cecchini RS, Atkins JN, Bevers TB, Fehrenbacher L, Pajon ER Jr, Wade JL 3rd, Robidoux A, Margolese RG, James J, Lippman SM, Runowicz CD, Ganz PA, Reis SE, McCaskill-Stevens W, Ford LG, Jordan VC, Wolmark N; National Surgical Adjuvant Breast and Bowel Project (NSABP)
  • Journal: Journal of the American Medical Association 2006 Jun 21;295(23):2727-41

2003 Publications

A Review of Selective Estrogen Receptor Modulators and National Surgical Adjuvant Breast and Bowel Project Clinical Trials

  • Author: Smith RE
  • Journal: Seminars in Oncology 2003 October;30(5 Suppl 16):4-13

Chemoprevention of Breast Cancer and the Trials of the National Surgical Adjuvant Breast and Bowel Project and Others

  • Author: Smith RE, Good BC
  • Journal: Endocrine-Related Cancer 2003 September;10(3)347-357

National Surgical Adjuvant Breast and Bowel Project Update: Prevention Trials and Endocrine Therapy of Ductal Carcinoma in Situ

  • Author: Vogel VG, Costantino JP, Wickerham DL, Cronin WM
  • Journal: Clinical Cancer Research 9(1 Pt 2):495S-501S, January 2003

2002 Publications

Tamoxifen Versus Raloxifene in the Prevention of Breast Cancer

  • Author: Wickerham DL
  • Journal: European Journal of Cancer 2002; 38 (Suppl 6): S20-S21

The Study of Tamoxifen and Raloxifene: Preliminary Enrollment Data From a Randomized Breast Cancer Risk Reduction Trial

  • Author: Vogel VG, Costantino JP, Wickerham DL, Cronin WM, Wolmark N
  • Journal: Clinical Breast Cancer 3(2):153-159, June, 2002

2001 Publications

Benefit/Risk Assessment of SERM Therapy: Clinical Trial Versus Clinical Practice Settings

  • Author: Costantino JP
  • Journal: Annals of the New York Academy of Sciences 949:280-285 December, 2001

Back to Top

< Previous Section


A Service of the National Cancer Institute
Department of Health and Human Services National Institutes of Health USA.gov